Regeneron lifts Eylea guidance, reports first Praluent sales

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported 3Q15 earnings and raised its sales guidance for Eylea aflibercept, but reported gradual uptake of PCSK9 inhibitor Praluent alirocumab. Regeneron lost $14 to $564 on Wednesday.

Regeneron lifted its 2015 Eylea U.S. net sales growth guidance to 50-55% from 45-50%. It said U.S. sales of Eylea were $734 million in 3Q15, up 65% from $445 million in 3Q14. Bayer (Xetra:BAYN) has ex-U.S. rights to the human fusion protein that binds all forms of VEGF-A and placental growth factor ( PGF; PIGF). ...